FluMist Quadrivalent, a vaccine developed by AstraZeneca plc's (AZN) MedImmune unit, has been approved by the FDA for the prevention of seasonal influenza in people aged 2 years through 49 years.
FluMist Quadrivalent is the first influenza vaccine to contain four strains of the influenza virus - two influenza A strains and two influenza B strains. All other currently available licensed seasonal influenza vaccines, are trivalent, containing only three influenza virus strains namely, two strains of influenza A and one of influenza B.
Some of the approved trivalent flu vaccines are CSL Biotherapies' Afluria; Novartis' Agriflu; GlaxoSmithKline's Fluarix; ID Biomedical Corp.'s FluLaval; MedImmune's FluMist, and Sanofi Pasteur Inc.'s Fluzone and Fluzone High-Dose.
According to federal health officials, FluMist Quadrivalent increases the likelihood of adequate protection against circulating influenza B strains.
The newly approved FluMist Quadrivalent is administered as a spray into the nose, similar to the trivalent FluMist vaccine.
Influenza, commonly referred to as flu, is a contagious viral infection, associated with aches, pains, tiredness, sore throat and a runny nose. The symptoms may last from three to five days and can make a person quite ill for a few weeks.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.